RT Journal Article
SR Electronic
T1 A Study on the Tolerability of Capecitabine plus Oxaliplatin as Adjuvant Chemotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1851
OP 1854
VO 36
IS 4
A1 MASAYOSHI NAKANISHI
A1 YOSHIAKI KURIU
A1 YASUTOSHI MURAYAMA
A1 TOMOHIRO ARITA
A1 TOSHIYUKI KOSUGA
A1 RYO MORIMURA
A1 HIROTAKA KONISHI
A1 SYUHEI KOMATSU
A1 ATSUSHI SHIOZAKI
A1 HISASHI IKOMA
A1 DAISUKE ICHIKAWA
A1 HITOSHI FUJIWARA
A1 KAZUMA OKAMOTO
A1 EIGO OTSUJI
YR 2016
UL http://ar.iiarjournals.org/content/36/4/1851.abstract
AB Aim: Tolerability, adverse events, and long-term outcomes were compared and analyzed between patients receiving oral anticancer agent-based adjuvant chemotherapy regimen (PO group) and those receiving combination adjuvant chemotherapy with oxaliplatin (OX group), after curative resection of colorectal cancer at our Department. Patients and Methods: The subjects included in the study were 169 patients with stage III colorectal cancer who underwent curative resection and received postoperative adjuvant chemotherapy between June 2007 and October 2014. Fifty-three patients were included in the OX group, while 116 patients were included in PO group. Results: No significant difference was observed in treatment completion rates. No significant difference in either the overall or relapse-free survival rates was observed between the two groups. Conclusion: Oxaliplatin has been shown to improve therapeutic outcomes after curative resection of colorectal cancer. Even compared to oral anticancer agents, oxaliplatin appears to be equal in tolerability and treatment completion rate.